The goal of this clinical trial is to learn the impact of tight versus less tight glycemic control on microvascular complications among Egyptian adults with uncontrolled T2DM. The main question it aims to answer is: Does tight glycemic control improve or worsens microvascular complications of diabetes compared to less tight glycemic control? Participants will: * Be divided to two groups according to their HbA1c group A tight glycemic control and less tight glycemic control. * Be followed for 6 months with clinical, laboratory, and fundoscopic evaluations performed at baseline and endpoint.
Background: Tight glycemic control is widely promoted in the management of type 2 diabetes mellitus (T2DM) to reduce microvascular complications, yet the extent and speed of HbA1c reduction may paradoxically exacerbate certain outcomes. Objective: To assess the impact of tight versus less tight glycemic control on microvascular complications among Egyptian adults with uncontrolled T2DM. Methods: In this randomized controlled trial, 80 patients with poorly controlled T2DM (HbA1c \>7.5%) were randomized into two groups: Group A (tight control, HbA1c \<7.0%) and Group B (less tight control, HbA1c \<7.5%). Participants were followed for 6 months with clinical, laboratory, and fundoscopic evaluations performed at baseline and endpoint.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
80
The effect of this intervention on HbA1c leading to either tight glycemic control HbA1c less than 7% or less tight glycemic control HbA1c less than 7.5%
Individualized adjustments in antidiabetic therapy, lifestyle modification, and monthly clinical follow-up.
Ain Shams University Hospitals
Cairo, Abbasya, Egypt
Effect of Tight Glycemic Control on Microvascular Complications (Retinopathy, neuropathy and Nephropathy) in Type 2 Diabetes Mellitus in 80 patients divided into two groups according to their HbA1c
80 patients with poorly controlled T2DM (HbA1c \>7.5%) were randomized into two groups according to their HbA1c: Group A (tight control, HbA1c \<7.0%) and Group B (less tight control, HbA1c \<7.5%). Participants were followed for 6 months with clinical, laboratory and fundoscopic evaluations performed at baseline and endpoint.
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.